314 related articles for article (PubMed ID: 31443496)
21. Profiling Oncogenic Germline Mutations in Unselected Chinese Lung Cancer Patients.
Yang J; Li H; Li B; Li W; Guo Q; Hu L; Song Z; Zhou B
Front Oncol; 2021; 11():647598. PubMed ID: 33898318
[TBL] [Abstract][Full Text] [Related]
22. Gene Fusion Detection in NSCLC Routine Clinical Practice: Targeted-NGS or FISH?
Pecciarini L; Brunetto E; Grassini G; De Pascali V; Ogliari FR; Talarico A; Marra G; Magliacane G; Redegalli M; Arrigoni G; Lazzari C; Gregorc V; Bulotta A; Doglioni C; Cangi MG
Cells; 2023 Apr; 12(8):. PubMed ID: 37190044
[TBL] [Abstract][Full Text] [Related]
23. ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma.
Dacic S; Villaruz LC; Abberbock S; Mahaffey A; Incharoen P; Nikiforova MN
Oncotarget; 2016 Dec; 7(50):82943-82952. PubMed ID: 27769042
[TBL] [Abstract][Full Text] [Related]
24. Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.
Cassidy RJ; Zhang X; Patel PR; Shelton JW; Escott CE; Sica GL; Rossi MR; Hill CE; Steuer CE; Pillai RN; Ramalingam SS; Owonikoko TK; Behera M; Force SD; Fernandez FG; Curran WJ; Higgins KA
Cancer; 2017 Oct; 123(19):3681-3690. PubMed ID: 28608966
[TBL] [Abstract][Full Text] [Related]
25. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas.
Mescam-Mancini L; Lantuéjoul S; Moro-Sibilot D; Rouquette I; Souquet PJ; Audigier-Valette C; Sabourin JC; Decroisette C; Sakhri L; Brambilla E; McLeer-Florin A
Lung Cancer; 2014 Feb; 83(2):168-73. PubMed ID: 24380695
[TBL] [Abstract][Full Text] [Related]
26. Clinical Utility of Cell-Free DNA for the Detection of
McCoach CE; Blakely CM; Banks KC; Levy B; Chue BM; Raymond VM; Le AT; Lee CE; Diaz J; Waqar SN; Purcell WT; Aisner DL; Davies KD; Lanman RB; Shaw AT; Doebele RC
Clin Cancer Res; 2018 Jun; 24(12):2758-2770. PubMed ID: 29599410
[No Abstract] [Full Text] [Related]
27. Translating Systems Medicine Into Clinical Practice: Examples From Pulmonary Medicine With Genetic Disorders, Infections, Inflammations, Cancer Genesis, and Treatment Implication of Molecular Alterations in Non-small-cell Lung Cancers and Personalized Medicine.
Pinsolle J; McLeer-Florin A; Giaj Levra M; de Fraipont F; Emprou C; Gobbini E; Toffart AC
Front Med (Lausanne); 2019; 6():233. PubMed ID: 31737634
[TBL] [Abstract][Full Text] [Related]
28. Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS.
Niu X; Chuang JC; Berry GJ; Wakelee HA
Curr Treat Options Oncol; 2017 Nov; 18(12):71. PubMed ID: 29143897
[TBL] [Abstract][Full Text] [Related]
29. Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing.
Cohen D; Hondelink LM; Solleveld-Westerink N; Uljee SM; Ruano D; Cleton-Jansen AM; von der Thüsen JH; Ramai SRS; Postmus PE; Graadt van Roggen JF; Hoppe BPC; Clahsen PC; Maas KW; Ahsmann EJM; Ten Heuvel A; Smedts F; van Rossem RN; van Wezel T
J Thorac Oncol; 2020 Jun; 15(6):1000-1014. PubMed ID: 32014610
[TBL] [Abstract][Full Text] [Related]
30. Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Non-small-cell Lung Cancer: Implications of FISH-positive Patterns.
Clavé S; Rodon N; Pijuan L; Díaz O; Lorenzo M; Rocha P; Taus Á; Blanco R; Bosch-Barrera J; Reguart N; de la Torre N; Oliveras G; Espinet B; Bellosillo B; Puig X; Arriola E; Salido M
Clin Lung Cancer; 2019 Jul; 20(4):e421-e429. PubMed ID: 30898567
[TBL] [Abstract][Full Text] [Related]
31. Hotspot Mutations Detectable by Next-generation Sequencing in Exhaled Breath Condensates from Patients with Lung Cancer.
Youssef O; Knuuttila A; Piirilä P; Böhling T; Sarhadi V; Knuutila S
Anticancer Res; 2018 Oct; 38(10):5627-5634. PubMed ID: 30275180
[TBL] [Abstract][Full Text] [Related]
32. Assessment of cytology based molecular analysis to guide targeted therapy in advanced non-small-cell lung cancer.
Li W; Zhang Z; Guo L; Qiu T; Ling Y; Cao J; Guo H; Zhao H; Li L; Ying J
Oncotarget; 2016 Feb; 7(7):8332-40. PubMed ID: 26789109
[TBL] [Abstract][Full Text] [Related]
33. Real-world utility of next-generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma.
Kim JH; Yoon S; Lee DH; Jang SJ; Chun SM; Kim SW
Cancer Med; 2021 May; 10(10):3197-3204. PubMed ID: 33960703
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive Molecular Characterization of Young Chinese Patients with Lung Adenocarcinoma Identified a Distinctive Genetic Profile.
Hou H; Zhu H; Zhao H; Yan W; Wang Y; Jiang M; Liu B; Liu D; Zhou N; Zhang C; Li P; Chang L; Guan Y; Wang Z; Zhang X; Li Z; Fang B; Zhang X
Oncologist; 2018 Sep; 23(9):1008-1015. PubMed ID: 29700208
[TBL] [Abstract][Full Text] [Related]
35. Economic Analysis of Tissue-First, Plasma-First, and Complementary NGS Approaches for Treatment-Naïve Metastatic Lung Adenocarcinoma.
Yang SC; Lin CC; Chen YL; Su WC
Front Oncol; 2022; 12():873111. PubMed ID: 35669427
[TBL] [Abstract][Full Text] [Related]
36. Combined targeted DNA and RNA sequencing of advanced NSCLC in routine molecular diagnostics: Analysis of the first 3,000 Heidelberg cases.
Volckmar AL; Leichsenring J; Kirchner M; Christopoulos P; Neumann O; Budczies J; Morais de Oliveira CM; Rempel E; Buchhalter I; Brandt R; Allgäuer M; Talla SB; von Winterfeld M; Herpel E; Goeppert B; Lier A; Winter H; Brummer T; Fröhling S; Faehling M; Fischer JR; Heußel CP; Herth F; Lasitschka F; Schirmacher P; Thomas M; Endris V; Penzel R; Stenzinger A
Int J Cancer; 2019 Aug; 145(3):649-661. PubMed ID: 30653256
[TBL] [Abstract][Full Text] [Related]
37. Mutation profile in liquid biopsy tested by next generation sequencing in Mexican patients with non-small cell lung carcinoma and its impact on survival.
Martínez-Herrera JF; Sánchez Domínguez G; Juárez-Vignon Whaley JJ; Carrasco-Cara Chards S; López Vrátný C; Guzmán Casta J; Riera Sala RF; Alatorre-Alexander JA; Seidman Sorsby A; Cruz Zermeño M; Conde Flores E; Flores-Mariñelarena RR; Sánchez-Ríos CP; Martínez-Barrera LM; Gerson-Cwilich R; Santillán-Doherty P; Jiménez López JC; López Hernández W; Rodríguez-Cid JR
J Thorac Dis; 2024 Jan; 16(1):161-174. PubMed ID: 38410597
[TBL] [Abstract][Full Text] [Related]
38. Targeted next-generation sequencing in cytology specimens for molecular profiling of lung adenocarcinoma.
Zhang Y; Li J; Hua P; Liu N; Li Q; Zhu X; Jiang L; Zheng K; Su X
Int J Clin Exp Pathol; 2018; 11(7):3647-3655. PubMed ID: 31949745
[TBL] [Abstract][Full Text] [Related]
39. MET Exon 14 Alterations and New Resistance Mutations to Tyrosine Kinase Inhibitors: Risk of Inadequate Detection with Current Amplicon-Based NGS Panels.
Poirot B; Doucet L; Benhenda S; Champ J; Meignin V; Lehmann-Che J
J Thorac Oncol; 2017 Oct; 12(10):1582-1587. PubMed ID: 28779874
[TBL] [Abstract][Full Text] [Related]
40. GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
Jiang J; Wu X; Tong X; Wei W; Chen A; Wang X; Shao YW; Huang J
Lung Cancer; 2018 Jan; 115():5-11. PubMed ID: 29290262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
